Study wrapper · #1372
Carbon Emission Impact of Semaglutide in People with Obesity in the UK Using a Disease Modelling Approach.
Editor's note
A Markov cohort model, not an empirical measurement — results hinge on assumptions drawn from the STEP and SELECT trials and on how emissions are attributed to healthcare resource use. Author affiliations suggest manufacturer involvement, which is worth weighing for an environmental-benefit framing. The finding that longer survival can raise lifetime emissions in the cardiovascular-disease population is an honest wrinkle that adds credibility to the modeling.
Plain-language abstract
This modeling study estimated the lifetime carbon footprint of adding semaglutide 2.4 mg to diet and exercise for people with obesity in the UK. In two of three modeled populations, fewer obesity-related complications more than offset the drug's manufacturing emissions, so lifetime emissions fell slightly while life expectancy improved; in the cardiovascular-disease group, longer survival modestly raised emissions.